N/A N=5,012 HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.
HIV/AIDS · Sexually Transmitted Infections
Primary: STI Incidence — 250; 226 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,838 Intervention to Retain HIV-positive Patients in Medical Care
Primary Care Appointment Keeping
Primary: The Percentage of Patients Attending a Primary Care Visit in Each of 3 Four-month Periods (First Measure) — 55.8; 55.6; 45.7 percent in care each 4 month period
Phase 2 N=34 AIDS 347: IL-6 Blockade in Treated HIV Infection
HIV Infections
Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
N/A N=120 FANMI: Community Cohort Care for HIV-Infected Adolescent Girls in Haiti
HIV
Primary: 12 Month Retention — 41; 44 Participants — p=0.55
N/A N=12 Psychosocial Intervention for Older HIV+ Adults With HAND
HIV/AIDS · Aging · Mild Cognitive Impairment
Primary: Feasibility - Session Attendance — 5; 5 Participants
Phase 2 N=160 Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regimen — 16; 18; 16; 7 Participants
N/A N=216 Treatment Advocacy Intervention for HIV-Positive African Americans
HIV
Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005
N/A N=21,726 Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations
HIV Infection
Primary: Proportion Reporting HIV Testing in the Prior 12 Months — 36.9; 26.2 percentage of participants — p=0.09
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 1 N=23 A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 3; 2; 2; 3 Participants
N/A N=306 Package of Resources for Assisted Contact Tracing: Implementation, Costs, and Effectiveness
Human Immunodeficiency Virus
Primary: Index Client Fidelity Assessment — 66.30; 45.70 score on a scale — p=<0.001
N/A N=34 DMID 21-0041; Influenza CVD 59000
Influenza
Primary: Viral Confirmation — 6; 0 Participants
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
Phase 2 N=43 Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…
N/A N=60 Adherence Connection for Counseling, Education, and Support (ACCESS) II
HIV Infections
Primary: Self-Reported ART Adherence — 56.67; 58.7 Percentage of successful doses
N/A N=175 Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America
HIV Infection · Human Immunodeficiency Virus 1 Positive · Malignant Neoplasm
Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…
Phase 3 N=64 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
HIV Infections · CMV Cytomegalovirus Retinitis
Primary: Survival — 6; 7; 3; 20 participants
N/A N=23 Sistas Informing Sistas on Topics About AIDS and Prevention (SISTA-P)
Health Behavior, Risky · Health Knowledge, Attitudes, Practice · Health-Related Behavior
Primary: Feasibility of the Intervention Scale — 4.78 units on a scale — p=.001
N/A N=439 Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women
Alcohol; Harmful Use · Binge Drinking · Risk Behavior
Primary: Change in Alcohol Use (Heavy Drinking Days) — 6; 6; 6; 3 heavy drinking days
Phase 1 N=18 Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
Distress · Depression · Grief
Primary: Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse…
N/A N=296 An Accessible Digital Intervention to Promote HIV Testing/Counseling and Prevention Among Adolescents
HIV Prevention
Primary: Attitudes Around HIV Testing and Counseling — 0.33; 0.33; 0.74; 0.26 score on a scale
N/A N=943 Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools
HIV Infection
Primary: Determination of the Prevalence of R5 and X4-tropic Variants of HIV in HIV-infected Population in Russia — 123; 85; 114; 78 participants
Early Phase 1 N=9 Autologous CD4 T-Cells in HIV (C34-CXCR4)
Hiv
Primary: The Number of Subjects With Treatment Related Adverse Events — 2; 1; 2 Participants
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
Phase 2 N=98 A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)
Latent Tuberculosis Bacteriology and Histology Unknown · Latent Tuberculosis
Primary: Number and Percentage of Unsolicited and Solicited Adverse Events Recorded Post Day 0 Vaccination. — 7; 8; 15; 15 Participants